BIODESIX INC (BDSX)
BIODESIX INC (BDSX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 25,555 | 28,755 | 59,744 | NaN |
| Direct costs and expenses (less employee related expenses and depreciation and amortization) | 2,712 | 3,438 | 8,634 | NaN |
| Employee related expenses (less share-based compensation expenses) | 19,209 | 18,121 | 48,703 | NaN |
| Contracted services expenses | 1,689 | 1,321 | 5,691 | NaN |
| Sales and marketing education and event expenses | 2,211 | 1,961 | 5,601 | NaN |
| Occupancy and equipment service expenses | 996 | 998 | 3,079 | NaN |
| Clinical trials and associated costs | 638 | 443 | 1,287 | NaN |
| Depreciation and amortization expense | 1,396 | 1,387 | 1,407 | NaN |
| Share-based compensation expenses | 1,115 | 1,075 | 3,064 | NaN |
| Interest expense | 1,977 | 2,059 | 5,657 | NaN |
| Change in fair value of warrant liability, net | NaN | 0 | 0 | NaN |
| Other segment items | 1,405 | 1,932 | 4,750 | NaN |
| Change in fair value of warrant liability, net | NaN | 0 | 0 | 280 |
| Net loss | -7,793 | -3,980 | -8,716 | -22,569 |
| Depreciation and amortization | 1,396 | 1,387 | 1,407 | 2,876 |
| Accretion of lease right-of-use assets | NaN | 19 | -29 | -59 |
| Reduction (accretion) of lease right-of-use assets | 19 | NaN | NaN | NaN |
| Share-based compensation expense | 1,115 | 1,075 | 1,053 | 2,011 |
| Provision for credit losses | 24 | 71 | 0 | 109 |
| Accrued interest, amortization of debt issuance costs and other | 332 | 333 | 332 | 639 |
| Inventory excess and obsolescence | 20 | 28 | 10 | 11 |
| Impairment loss on intangible assets | 5 | 1 | 7 | 99 |
| Accounts receivable | 488 | -3,608 | 5,224 | -1,085 |
| Other current assets | 1,366 | 592 | -16 | -318 |
| Other long-term assets | -19 | -9 | 125 | 5 |
| Accounts payable and other accrued liabilities | -2,344 | 974 | 486 | 399 |
| Deferred revenue | -766 | -1,840 | 2,128 | -114 |
| Current and long-term operating lease liabilities | -341 | -315 | -224 | -250 |
| Net cash, cash equivalents, and restricted cash used in operating activities | -10,168 | 778 | -8,879 | -15,170 |
| Purchase of property and equipment | 81 | 86 | 48 | 125 |
| Patent costs and intangible asset acquisition, net | 63 | 18 | 19 | 107 |
| Net cash, cash equivalents, and restricted cash used in investing activities | -144 | -104 | -67 | -232 |
| Proceeds from term loan and notes payable | NaN | 0 | 0 | 10,000 |
| Proceeds from the issuance of common stock | 17,214 | 2,320 | 5,000 | NaN |
| Proceeds from issuance of common stock under employee stock purchase plan | 354 | 0 | 184 | 313 |
| Proceeds from exercise of stock options | 1 | NaN | NaN | NaN |
| Repayment of term loan and notes payable | 5 | 5 | 4 | 12 |
| Payment of debt issuance costs | 28 | 0 | 3 | 27 |
| Equity financing costs | 481 | 344 | 188 | NaN |
| Other | -158 | -262 | -167 | -388 |
| Net cash, cash equivalents, and restricted cash provided by financing activities | 16,897 | 1,709 | 4,822 | 9,886 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 6,585 | 2,383 | -4,124 | -5,516 |
| Cash, cash equivalents, and restricted cash beginning of period | 19,075 | 16,692 | 26,332 | NaN |
| Cash, cash equivalents, and restricted cash end of period | 25,660 | 19,075 | 16,692 | NaN |